tiprankstipranks
Trending News
More News >
Theravance Biopharma (TBPH)
NASDAQ:TBPH
US Market

Theravance Biopharma (TBPH) Financial Statements

Compare
356 Followers

Theravance Biopharma Financial Overview

Theravance Biopharma's market cap is currently $747.42M. The company's EPS TTM is $1.15; its P/E ratio is 8.89; Theravance Biopharma is scheduled to report earnings on March 19, 2026, and the estimated EPS forecast is $-0.03. See an overview of income statement, balance sheet, and cash flow financials.
Dec 25Dec 24Dec 23Dec 22Dec 21
Income Statement
Total Revenue$ 107.46M$ 64.38M$ 57.42M$ 51.35M$ 55.31M
Gross Profit$ 0.00$ 64.38M$ 16.80M$ -12.05M$ -138.35M
Operating Income$ -3.60M$ -46.95M$ -56.03M$ -91.96M$ -257.78M
EBITDA$ -3.60M$ -38.45M$ -51.65M$ -76.08M$ -232.83M
Net Income$ 105.89M$ -56.42M$ -55.19M$ 872.13M$ -199.43M
Balance Sheet
Cash & Short-Term Investments$ 315.36M$ 88.35M$ 102.43M$ 327.48M$ 173.47M
Total Assets$ 485.57M$ 354.16M$ 382.00M$ 607.40M$ 374.82M
Total Debt$ 42.70M$ 49.82M$ 49.16M$ 52.16M$ 669.52M
Net Debt$ -125.10M$ 12.02M$ 9.61M$ -246.01M$ 579.56M
Total Liabilities$ 188.85M$ 178.62M$ 169.00M$ 165.60M$ 713.39M
Stockholders' Equity$ 296.72M$ 175.54M$ 213.00M$ 441.80M$ -338.57M
Cash Flow
Free Cash Flow$ 238.50M$ -11.87M$ -29.48M$ -187.56M$ -211.26M
Operating Cash Flow$ 238.54M$ -11.54M$ -27.00M$ -186.99M$ -207.86M
Investing Cash Flow$ -105.28M$ 12.28M$ -32.70M$ 1.15B$ 124.49M
Financing Cash Flow$ -3.25M$ -2.50M$ -198.93M$ -758.81M$ 91.86M
Currency in USD

Theravance Biopharma Earnings and Revenue History

Theravance Biopharma Debt to Assets

Theravance Biopharma Cash Flow

Theravance Biopharma Forecast EPS vs Actual EPS